Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
T.PYR: Contract Toward Titanium Powder Supply & Distribution Agreement with Asian Materials Co. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Nutriband Inc NTRBW


Primary Symbol: NTRB

Healthcare Biotechnology
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA... see more

Recent & Breaking News (NDAQ:NTRB)

Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

GlobeNewswire 10 days ago

Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

GlobeNewswire March 18, 2026

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

GlobeNewswire February 17, 2026

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

GlobeNewswire January 30, 2026

Nutriband CEO Publishes Letter to Shareholders

GlobeNewswire December 31, 2025

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

GlobeNewswire December 29, 2025

Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

GlobeNewswire December 18, 2025

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

GlobeNewswire December 18, 2025

Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference

Newsfile November 24, 2025

REPEAT - Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

GlobeNewswire October 28, 2025

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

GlobeNewswire October 28, 2025

Nutriband Co-Founder Gareth Sheridan Returns as CEO

GlobeNewswire October 27, 2025

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

GlobeNewswire October 10, 2025

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

GlobeNewswire October 8, 2025

Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference

GlobeNewswire October 8, 2025

11 Company Presentations Today at The MicroCap Rodeo Conference

ACCESS Newswire September 25, 2025

Nutriband Inc. to Present at the MicroCap Rodeo Conference

GlobeNewswire September 24, 2025

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

GlobeNewswire September 10, 2025

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

GlobeNewswire September 3, 2025

Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

GlobeNewswire August 18, 2025

Podcasts